Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Intangibles (2016 - 2026)

Iradimed has reported Intangibles over the past 14 years, most recently at $3.3 million for Q1 2026.

  • Quarterly Intangibles fell 27.02% to $3.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, down 27.02% year-over-year, with the annual reading at $3.4 million for FY2025, 20.99% down from the prior year.
  • Intangibles was $3.3 million for Q1 2026 at Iradimed, down from $3.4 million in the prior quarter.
  • Over five years, Intangibles peaked at $4.8 million in Q3 2025 and troughed at $1.3 million in Q1 2022.
  • The 5-year median for Intangibles is $3.3 million (2026), against an average of $3.1 million.
  • Year-over-year, Intangibles soared 129.68% in 2023 and then fell 27.02% in 2026.
  • A 5-year view of Intangibles shows it stood at $2.1 million in 2022, then soared by 67.73% to $3.5 million in 2023, then increased by 23.39% to $4.3 million in 2024, then decreased by 20.99% to $3.4 million in 2025, then fell by 2.9% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Intangibles are $3.3 million (Q1 2026), $3.4 million (Q4 2025), and $4.8 million (Q3 2025).